Skip to main content

HSA's Regulatory Information and Consumer Advisories on COVID-19

You can find the latest COVID-19 related guidances, advisories, updates and general information for dealers, healthcare professionals and consumers on this page.

General Updates

Vaccines

HSA extends the use of Comirnaty COVID-19 Vaccine by Pfizer-BioNTech to Children of Ages 5 to 11

HSA grants interim authorisation for Sinovac-CoronaVac vaccine in Singapore

HSA approves “Comirnaty” as the new brand name for Pfizer-BioNTech's COVID-19 vaccine

HSA approves “Spikevax” as the new brand name for Moderna's COVID-19 vaccine

HSA approves new storage condition for the Pfizer-BioNTech COVID-19 vaccine at refrigerator temperature for up to 31 days

HSA extends the use of Pfizer-BioNTech COVID-19 vaccine to adolescents of ages 12 to 15

HSA safety update on COVID-19 vaccines

Approval of updated storage condition for the Pfizer-BioNTech COVID-19 vaccine

HSA grants interim authorisation for Moderna COVID-19 vaccine in Singapore

HSA’s Pandemic Special Access Route (PSAR) facilitates Singapore's access to critical novel vaccines, medicines and medical devices

How COVID-19 vaccine development and Pandemic Special Access Route (PSAR) interim authorisation have expedited access to vaccines

HSA grants interim authorisation for first COVID-19 vaccine in Singapore

Factsheets for healthcare professionals and vaccine recipients

Medical Devices

HSA grants provisional authorisation for ‘BreFence Go COVID-19 Breath Test System’ and ‘TracieX Breathalyser’ for detection of COVID-19 infection

HSA grants interim authorisation for four COVID-19 antigen rapid test self-test kits

List of surgical masks manufactured by local licensed manufacturers

Others

HSA grants interim authorisation for casirivimab and imdevimab for treatment of COVID-19 infection

HSA grants interim authorisation for Sotrovimab for treatment of COVID-19 infection

HSA grants conditional approval of Remdesivir for treatment of COVID-19 infection

Collaborations with ICMRA (International Coalition of Medicines Regulatory Authorities

For Consumers

HSA advisory on Lianhua Qingwen products for prevention or treatment of COVID-19

Advisory on the use of ivermectin for COVID-19

COVID-19 self-test kits authorised for use in Singapore

What you need to know about masks

COVID-19 vaccine side effect self-reporting form

Advisory on herbal products claiming to prevent or treat COVID-19

Proper use and storage of alcohol-based hand sanitisers

Advisory on products claiming to prevent or treat COVID-19

Guide to masks and respirators

For the Industry

COVID-19 test kits authorised for professional use

Guidance on the import of surgical masks, hand sanitisers, respirators, thermometers and protective gear

Guidance on the supply of respiratory devices

Guidance on 3-D printing of essential medical devices and accessories for use in COVID-19 situation

Guidance on medical devices for decontamination of single use respirators during the COVID-19 situation

HSA CEO messages on facilitating development and access to COVID-19 related therapeutic products and devices

For Healthcare Professionals

Dear Healthcare Professional Letter - PSAR interim authorisation of CoronaVac for active immunisation to prevent COVID-19 disease in Singapore

Dear Healthcare Professional Letter - PSAR interim authorisation of casirivimab and imdevimab infusion for COVID-19 infection in Singapore

Dear Healthcare Professional Letter - Interim authorisation of sotrovimab infusion for COVID-19 infection in Singapore

Special Access Route (SAR) for unauthorised COVID-19 vaccines

Dear Healthcare Professional Letter - Interim authorisation of Pfizer-BioNTech COVID-19 Vaccine extended to include use in adolescents aged 12 to 15 years

Dear Healthcare Professional Letter - Interim authorisation of Moderna COVID-19 vaccine for active immunisation to prevent COVID-19 disease in Singapore

Dear Healthcare Professional Letter - Monitoring the safety profile of COVID-19 vaccines

Dear Healthcare Professional Letter - Interim authorisation of Pfizer-BioNTech COVID-19 vaccine (BNT162b2) for active immunisation to prevent COVID-19 disease in Singapore

Report vaccine adverse events

Last updated: 31 Dec 2018